I wish people would stop with these doom and gloom articles.
Lifespan estimations are based on historic data. The latest study quoted in the article is 2015. Six years ago, CGMs were rare in the Uk whereas today, more than 20% of people with Type 1 use them. Six years ago, NovoRapid was considered a fast acting insulin; now it is common to refer to it as NovoSluggish.
My point is that treatment for Type 1 diabetes is changing fast. Predictions based on historic data are flawed. If articles like this continue to be published, they should start with information about improved treatment rather than hiding it at the bottom where few people will read it because they are too scared after reading about their significantly reduced lifespan.
Yes, diabetes can cause very nasty complications but we have the tools to reduce the risk.
@Pura Vida forgive me, my comments are not aimed at you. I just wish journalists would realise the harm such articles can cause to someone newly diagnosed who may already be experiencing anxiety.